Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)

Sutro Biopharma's Current Deferred Revenue history spans 9 years, with the latest figure at $9.0 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 87.63% year-over-year to $9.0 million; the TTM value through Sep 2025 reached $9.0 million, down 87.63%, while the annual FY2024 figure was $69.8 million, 237.67% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $9.0 million at Sutro Biopharma, down from $12.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $74.0 million in Q2 2024 and bottomed at $5.5 million in Q4 2021.
  • The 5-year median for Current Deferred Revenue is $16.8 million (2022), against an average of $25.6 million.
  • The largest annual shift saw Current Deferred Revenue surged 310.09% in 2024 before it crashed 87.63% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $5.5 million in 2021, then skyrocketed by 204.93% to $16.8 million in 2022, then grew by 23.31% to $20.7 million in 2023, then skyrocketed by 237.67% to $69.8 million in 2024, then plummeted by 87.14% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Current Deferred Revenue are $9.0 million (Q3 2025), $12.0 million (Q2 2025), and $69.0 million (Q1 2025).